Thymoglobulin®

BIOLOGICAL2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

Kidney TransplantKidney TransplantationRenal Transplant Recipients

Phase 2

Effects of Inhibiting Early Inflammation in Kidney Transplant Patients

CompletedNCT02495077

National Institute of Allergy and Infectious Diseases (NIAID)Kidney Transplant

Start: 2015-11-02End: 2021-07-23Updated: 2022-08-16

Selective CD28 Blockade in Renal Transplant Recipients

WithdrawnNCT04903054

National Institute of Allergy and Infectious Diseases (NIAID)Kidney Transplantation, Renal Transplant Recipients

Start: 2022-01-10End: 2022-09-22Updated: 2023-03-22

Related Papers

Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial

Journal of the American Society of Nephrology2022-10-0424 citations